Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imipenem/cilastatin/relebactam versus piperacillin/tazobactam for hospital-acquired or ventilator-associated bacterial pneumonia
2015-000246-34Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2015
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) comparing Imipenem/cilastatin/relebactam with Piperacillin/tazobactam (2 arms). Primary endpoints: All-cause mortality through Day 28 and Survival status through Day 28. Started Jun 2015; status: completed.
02
Drugs
imipenem + cilastatin + relebactampiperacillin + tazobactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2015-000246-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000246-34.